PDS Biotechnology Corporation
PDSB
$0.29
-$0.01-2.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.92% | -9.75% | -9.00% | -5.67% | -11.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.78% | -18.03% | -13.15% | -18.13% | -13.70% |
| Operating Income | 18.78% | 18.03% | 13.15% | 18.13% | 13.70% |
| Income Before Tax | 10.85% | 11.13% | 7.31% | 12.96% | 9.09% |
| Income Tax Expenses | 100.00% | 100.00% | -34.58% | -34.58% | -34.58% |
| Earnings from Continuing Operations | 8.01% | 6.03% | 8.28% | 13.98% | 10.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.01% | 6.03% | 8.28% | 13.98% | 10.02% |
| EBIT | 18.78% | 18.03% | 13.15% | 18.13% | 13.70% |
| EBITDA | 18.81% | 18.06% | 13.18% | 18.16% | 13.73% |
| EPS Basic | 29.62% | 28.01% | 27.18% | 29.81% | 25.13% |
| Normalized Basic EPS | 31.78% | 31.82% | 26.07% | 28.76% | 24.22% |
| EPS Diluted | 29.62% | 28.01% | 27.18% | 29.81% | 25.13% |
| Normalized Diluted EPS | 31.78% | 31.82% | 26.07% | 28.76% | 24.22% |
| Average Basic Shares Outstanding | 30.43% | 31.91% | 26.80% | 22.00% | 19.86% |
| Average Diluted Shares Outstanding | 30.43% | 31.91% | 26.80% | 22.00% | 19.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |